PUBLISHER: The Business Research Company | PRODUCT CODE: 2098845
PUBLISHER: The Business Research Company | PRODUCT CODE: 2098845
Rheolytic thrombectomy is a minimally invasive vascular intervention performed to extract blood clots (thrombi) from blood vessels through the use of a high-speed saline jet mechanism. The forceful saline stream breaks down the clot while simultaneously removing the fragmented material through aspiration, thereby helping restore normal circulation. It is frequently utilized in conditions such as deep vein thrombosis and pulmonary embolism where prompt clot extraction is required.
The primary product types of rheolytic thrombectomy include rheolytic thrombectomy devices, aspiration thrombectomy devices, mechanical thrombectomy devices, and ultrasonic thrombectomy devices. Rheolytic thrombectomy devices refer to catheter-based systems that utilize high-speed saline jets to break down and extract blood clots from blood vessels. These devices are used across procedures including acute limb ischemia, chronic limb ischemia, coronary thrombectomy, and pulmonary embolism and cater to patient groups such as adults, elderly populations, and pediatric patients. The applications include cardiovascular, peripheral vascular, neurovascular, and pulmonary embolism procedures and they are used by end users such as hospitals, ambulatory surgical centers, specialty clinics, and research institutions.
Tariffs are influencing the rheolytic thrombectomy market by increasing costs of imported catheter systems, saline jet technologies, medical-grade materials, and interventional vascular equipment required for thrombectomy procedures. This is elevating manufacturing and procurement expenses across rheolytic, aspiration, mechanical, and ultrasonic thrombectomy device segments. Device-intensive categories and regions reliant on imported medical technologies, particularly Asia-Pacific and Latin America, are experiencing pronounced impact due to global supply chain dependence. However, tariffs are also encouraging domestic manufacturing expansion, regional supplier diversification, and increased investment in local medical device production capabilities, supporting long-term market stability.
The rheolytic thrombectomy market size has grown rapidly in recent years. It will grow from $1.14 billion in 2025 to $1.26 billion in 2026 at a compound annual growth rate (CAGR) of 10.6%. The growth in the historic period can be attributed to increasing occurrence of thrombotic disorders, rising burden of cardiovascular diseases, increasing uptake of minimally invasive procedures, progress in interventional vascular technologies, greater availability of specialized vascular care centers.
The rheolytic thrombectomy market size is expected to see rapid growth in the next few years. It will grow to $1.9 billion in 2030 at a compound annual growth rate (CAGR) of 10.9%. The forecast period growth can be attributed to the increasing prevalence of deep vein thrombosis and pulmonary embolism, rising need for fast clot extraction procedures, advancements in thrombectomy device technologies, growing investments in healthcare infrastructure, and expanding use of image-guided vascular interventions. Key trends during the forecast period include improvements in catheter-based clot removal systems, rising preference for minimally invasive thrombectomy techniques, development of high-efficiency saline jet mechanisms, wider adoption of rapid blood flow restoration methods, and increased application of thrombectomy in peripheral vascular procedures.
The rising prevalence of cardiovascular diseases is expected to propel the growth of the rheolytic thrombectomy market going forward. Cardiovascular diseases (CVDs) refer to a group of disorders affecting the heart and blood vessels, including conditions such as coronary artery disease, stroke, heart failure, and hypertension. The rising prevalence of cardiovascular diseases is primarily due to unhealthy lifestyles, which negatively affect heart health and increase the risk of developing heart-related disorders. Rheolytic thrombectomy contributes to the management of cardiovascular diseases by rapidly dissolving and removing blood clots from occluded vessels using high-velocity saline jets and suction, thereby restoring normal blood flow, reducing ischemic damage, and improving patient outcomes in acute thrombotic conditions. For instance, in March 2025, according to the Joint Strategic Needs Assessment, a UK-based community health center, the number of deaths caused by cardiovascular disease (CVD) was 185 in 2023, compared to 178 recorded in 2022. Therefore, the increasing prevalence of cardiovascular diseases is driving the growth of the rheolytic thrombectomy market.
The rising burden of thrombotic conditions is expected to propel the growth of the rheolytic thrombectomy market going forward. Thrombotic disorders refer to medical conditions in which abnormal blood clots form inside blood vessels, disrupting normal blood flow. The burden of thrombotic conditions is growing due to an aging population, as older individuals are more prone to reduced blood flow, vascular damage, and underlying conditions that increase the risk of abnormal blood clot. Rheolytic thrombectomy enhances the management of thrombotic conditions by rapidly fragmenting and aspirating blood clots to restore vessel patency and improve downstream blood flow in acute vascular occlusions. For instance, in December 2025, according to the National Health Service (NHS) England, a UK-based government department, venous thromboembolism (VTE) risk assessment coverage in England reached 92% in Quarter 3 (October to December 2025) of 2025/26, with 3.4 million out of 3.7 million admitted patients being assessed on admission. Therefore, the rising prevalence of thrombotic disorders is driving the growth of the rheolytic thrombectomy market.
The increasing aging population is expected to propel the growth of the rheolytic thrombectomy market going forward. An aging population refers to a demographic structure in which the proportion of elderly individuals is higher than the proportion of younger individuals. The increasing aging population is primarily driven by rising life expectancy, as people are living longer and more individuals are reaching older age groups. Rheolytic thrombectomy enables rapid mechanical and pharmacochemical removal of blood clots to restore vascular flow, addressing the growing burden of age-related thrombotic disorders in the aging population. For instance, in February 2025, according to the World Health Organization, a Switzerland-based intergovernmental organization, the number of people aged 60 years and older worldwide is projected to increase from 1.1 billion in 2023 to 1.4 billion by 2030. Therefore, the increasing aging population is driving the growth of the rheolytic thrombectomy market.
Major companies operating in the rheolytic thrombectomy market are Johnson & Johnson, Abbott Laboratories, Medtronic plc, Koninklijke Philips N.V., Stryker Corporation, Becton Dickinson and Company, Boston Scientific Corporation, Terumo Corporation, Edwards Lifesciences, Teleflex Incorporated, Penumbra Inc., Inari Medical Inc., AngioDynamics Inc., Surmodics Inc., LeMaitre Vascular Inc., Imperative Care Inc., Argon Medical Devices Inc., Acandis GmbH & Co. KG, Vesalio LLC
North America was the dominant region in the rheolytic thrombectomy market in 2025. Asia-Pacific is expected to be the rapidly expanding region in the forecast period. The regions covered in rheolytic thrombectomy report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the rheolytic thrombectomy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The rheolytic thrombectomy market consists of revenues earned by entities by providing services such as catheter-based clot removal, emergency thrombectomy procedures, treatment of deep vein thrombosis and pulmonary embolism, peripheral arterial clot extraction, and post-procedure vascular care. The market value includes the value of related goods sold by the service provider or included within the service offering. The rheolytic thrombectomy market also includes sales of thrombectomy console systems, pump and power pulse delivery systems, aspiration and collection systems, and accessory kits and disposables. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
The rheolytic thrombectomy market research report is one of a series of new reports from The Business Research Company that provides rheolytic thrombectomy market statistics, including rheolytic thrombectomy industry global market size, regional shares, competitors with a rheolytic thrombectomy market share, detailed rheolytic thrombectomy market segments, market trends and opportunities, and any further data you may need to thrive in the rheolytic thrombectomy industry. This rheolytic thrombectomy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Rheolytic Thrombectomy Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses rheolytic thrombectomy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for rheolytic thrombectomy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The rheolytic thrombectomy market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.